Lapatinib

Lapatinib Increases Overall Survival in Metastatic Breast Cancer Patients With HER2-Positive Circulating Tumor Cells

Retrieved on: 
Thursday, January 4, 2024
Diagnosis, Clinical chemistry, Patient, Chinese, Lapatinib, Biology, Medical laboratory, AACC, Cancer, Medical imaging

WASHINGTON, Jan. 4, 2024 /PRNewswire/ -- A new study shows that lapatinib, a drug used for the treatment of metastatic HER2-positive cancer, is associated with improved overall survival in patients with initially HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells (CTCs). This groundbreaking finding was published today in a special issue of the Association for Diagnostics & Laboratory Medicine's (formerly AACC's) Clinical Chemistry journal titled "Cancer: Biology & Diagnostics."

Key Points: 
  • Findings published in the special "Cancer: Biology & Diagnostics" issue of ADLM's Clinical Chemistry journal
    WASHINGTON, Jan. 4, 2024 /PRNewswire/ -- A new study shows that lapatinib, a drug used for the treatment of metastatic HER2-positive cancer, is associated with improved overall survival in patients with initially HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells (CTCs).
  • This groundbreaking finding was published today in a special issue of the Association for Diagnostics & Laboratory Medicine's (formerly AACC's) Clinical Chemistry journal titled "Cancer: Biology & Diagnostics."
  • View the full study here: https://doi.org/10.1093/clinchem/hvad144

X-Chem Appoints Chief Scientific Officer and Chief Financial Officer

Retrieved on: 
Thursday, August 10, 2023
Research, Technology, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Artificial Intelligence, Chem, GSK, IBM, Biochemistry, CSO, Pharmacokinetics, Multimedia, Hagerman, UA, Patient, Drug discovery, CFO, MUSC, Management, Fine chemical, Lapatinib

X-Chem , the leading provider of innovative solutions in early-stage drug discovery, announced the addition of Karen Lackey as chief scientific officer (CSO) and David Hagerman as chief financial officer (CFO) to its global executive management team.

Key Points: 
  • X-Chem , the leading provider of innovative solutions in early-stage drug discovery, announced the addition of Karen Lackey as chief scientific officer (CSO) and David Hagerman as chief financial officer (CFO) to its global executive management team.
  • View the full release here: https://www.businesswire.com/news/home/20230810633082/en/
    David Hagerman and Karen Lackey join X-Chem as chief financial officer (CFO) and chief scientific officer (CSO), respectively.
  • Lackey’s career encompasses senior leadership roles within pharma (GSK, Roche), academia (MUSC, UA), biotech and most recently, with CRO Evotec.
  • He also served as a divisional CFO at clinical CRO Parexel and spent 16 years with IBM in a number of financial roles.

ACE-Breast-02 Pivotal Phase 3 Study of Ambrx’s ARX788 for the Treatment of HER2 Positive Metastatic Breast Cancer Achieves Positive Results

Retrieved on: 
Wednesday, March 1, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Clinical trial, Marketing, Breast cancer, BIRC, Stomach, NYSE, Trastuzumab, Capecitabine, Lapatinib, FDA, Patient, Taxane, Therapure BioPharma Inc, IDMC, ADC, PFS, HER2, National Medical Products Administration, Communication, NMPA, Pharmaceutical industry, Medical imaging

ACE-Breast-02 is a randomized, controlled pivotal Phase 3 clinical trial of humanized anti-HER2 monoclonal antibody-AS269 conjugate (ARX788) in the treatment of HER2 positive patients with locally advanced or metastatic breast cancers in China.

Key Points: 
  • ACE-Breast-02 is a randomized, controlled pivotal Phase 3 clinical trial of humanized anti-HER2 monoclonal antibody-AS269 conjugate (ARX788) in the treatment of HER2 positive patients with locally advanced or metastatic breast cancers in China.
  • The trial enrolled 441 HER2 positive breast cancer patients who have been previously treated with taxane and trastuzumab.
  • The positive results from this large Phase 3 study provide further support for our rationale to develop ARX788 globally in HER2 positive breast cancer patients.”
    ARX788 is an anti-HER2 ADC currently being studied broadly in breast cancer, gastric/GEJ cancer and other solid tumor clinical trials with our partner NovoCodex.
  • The United States Food and Drug Administration (FDA) has granted Fast Track Designation for ARX788 in HER2 positive metastatic breast cancer and Orphan Drug Designation for ARX788 in gastric cancer.

Global HER2 Antibodies Market Report 2022: Technological Advancements Such as Introduction of Hybrid Imaging Technique & Immunotherapies Present Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 8, 2022
Health, Oncology, Everolimus, Industry, Ansoff Matrix, Growth, CAGR, Lapatinib, Introduction, Trastuzumab emtansine, Market development, Geography, Treatment, USD, Institute of Information Technology Advancement, SWOT, Investment, Antibody, Type, Risk, Global, Fine chemical, Trastuzumab

Technological Advancements Such as Introduction of Hybrid Imaging Technique, Immunotherapies

Key Points: 
  • Technological Advancements Such as Introduction of Hybrid Imaging Technique, Immunotherapies
    The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score.
  • The report presents a detailed Ansoff matrix analysis for the Global HER2 Antibodies Market.
  • The analyst analyses the Global HER2 Antibodies Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.

Actinium Appoints Seasoned Leader Caroline Yarbrough as Chief Commercial Officer to Spearhead Iomab-B Commercialization

Retrieved on: 
Wednesday, November 2, 2022
Actinium, GSK, Pazopanib, Survival, Bristol Myers Squibb, CD45, Breast cancer, MBA, Leadership, Merck & Co., Chronic myelogenous leukemia, McKesson Corporation, Lymphatic system, Immunology, Emory University, NYSE, Renal cell carcinoma, Cure, DCR, Hematology, Degenerative disease, Goizueta Business School, BMT, University, AML, Prognosis, International business, Company, GlaxoSmithKline, Nyenrode Business University, Caroline, Patient, Acute myeloid leukemia, Multiple myeloma, BMS, Neuroscience, CML, Biotechnology, ViroPharma, Pharmaceutical industry, Lapatinib, Merck, Biology, Novartis

NEW YORK, Nov. 2, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced the appointment of Caroline Yarbrough as Chief Commercial Officer. Caroline joins Actinium from Novartis where she most recently served as Portfolio General Manager, US Oncology, with full P&L responsibility of a diverse portfolio of brands and development assets with revenues in excess of a billion dollars. Previously, she led the chronic myelogenous leukemia (CML) portfolio, a billion-dollar business comprising TASIGNA® and SCEMBLIX®. She also led strategic account management during the launch period for KYMRIAH®, the first approved CAR-T cell therapy.

Key Points: 
  • Given, this opportunity, a person of Caroline's caliber and skill set is the right commercial leader for Actinium at this time."
  • "Caroline's broad commercial expertise includes building organizations and successful launches in a variety of cancer treatment settings including hematology, CAR-T cellular therapy and rare diseases.
  • For nearly a decade, Caroline held roles at BMS leading commercial activities in neuroscience, immunology, multiple myeloma, CML and other solid tumors.
  • Caroline Yarbrough added, "I feel fortunate to become a key part of the Actinium team and lead its efforts to commercialize this potentially transformational radiotherapy.

INmune Bio, Inc. Presents Data on Combination Therapy with INB03™ on Overcoming Resistance to HER2 Targeted Therapies in Breast Cancer

Retrieved on: 
Thursday, June 16, 2022
HERE, Security (finance), MUC4, Science, Trastuzumab, Survival, TNF, Disease, Marketing, Inflammation, Neoplasm, Toxicity, GLOBE, ADC, Lapatinib, CEO, Private Securities Litigation Reform Act, NASDAQ, Tyrosine, Natural killer cell, FDA, HER2, MDSC, TME, Biomarker, Patient, TILS, U.S. Securities and Exchange Commission, TAM, Blood, Woman, Breast cancer, Risk, US Foods, NK, Tucatinib, Tumor microenvironment, Company, Cancer, Instituto de Biología y Medicina Experimental, Research, Data, Food, Medical imaging, Pharmaceutical industry, Vaccine, BC, Bedside, Immunotherapy

Boca Raton, Florida, June 16, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, has been invited to present data on reversing resistance to HER2 targeted immunotherapy at the HER2 Targeted Therapy Summit in Boston.  

Key Points: 
  • In pre-clinical models of trastuzumab resistant MUC4 HER2+ breast cancer, treatment with INB03 decreases MUC4 expression, reverses resistance to trastuzumab based therapies, and promotes an immunologically active TME.
  • Data presented at noon today at the HER2 Targeted Therapy Summit in Boston.
  • The presentation will present both the science driving MUC4-based resistance mechanisms and the translation of these pre-clinical studies to the clinic.
  • We have identified three reversable resistance mechanisms in women with HER2+/MUC+ breast cancer resistance to trastuzumab, resistance to tyrosine kinaseinhibitors(eg: lapatinib and tucatinib) and a cold immunosuppressive TME.

HER2+ Breast Cancer Disease Market Analysis Research Report 2021 - Pipeline Drugs will Face Strong Competition in a Saturated Market - ResearchAndMarkets.com

Retrieved on: 
Friday, January 28, 2022
Pharmaceutical, Health, Oncology, Breast cancer, Brain, Puma Biotechnology, Patient, Roche, Probability, Lapatinib, Population, Neratinib, Diarrhea, AstraZeneca, Phase, Trastuzumab, Survival, Daiichi Sankyo, Dietary supplement, Pharmaceutical industry, Trastuzumab emtansine, Pertuzumab/trastuzumab/hyaluronidase, Margetuximab

The publisher estimates that in 2018, there were 2.1 million incident cases and 8.6 million five-year prevalent cases of breast cancer worldwide.

Key Points: 
  • The publisher estimates that in 2018, there were 2.1 million incident cases and 8.6 million five-year prevalent cases of breast cancer worldwide.
  • By 2027, incident and five-year prevalent cases of breast cancer are expected to increase to 2.3 million and 9.3 million cases, respectively.
  • Furthermore, the market for HER2+ breast cancer is also becoming increasingly crowded, creating fierce competition among approved and pipeline therapies.
  • Breast cancer drugs, on average, take 9.7 years from Phase I to approval, compared to 9.6 years in the overall oncology space.

Improved Pharma Announces Pharmaceutical R&D Efforts in 2021

Retrieved on: 
Friday, January 14, 2022
Research, AAPS PharmSciTech, PDF, Canadian International Council, Poly, Excipient, DSC, Sumitomo Chemical, Lapatinib, Plasma, Salt (chemistry), Efficiency, Environment, SSCI, Bedaquiline, THF, Particle-size distribution, X-ray crystallography, Dow Chemical Company, Risk, FBZ, XRD, Publication, Adult, AAPS, NMR, Ion, Pharmacy, Solubility, ASD, Section, Tuberculosis, Solvent, RH, Ageing, PEO Soldier, Solution, Computer scientist, NCL, TGA, International Journal of Pharmaceutics, Behavior, IR, Particle size, ADFS, Journal, CSO, Atomic mass, USFDA, Niclosamide, TB, Tablet, Population, PEO, Salt, Consultant, Polymer, ADF, Drug development, Heckel, Patent, Journal of Pharmaceutical Sciences, Ethylene oxide, Pharmaceutical industry, Fine chemical, Sulfur, Animal, Aluminium, Indometacin

WEST LAFAYETTE, Ind., Jan. 14, 2022 /PRNewswire-PRWeb/ -- Developing new tools and advancing pharmaceutical development is a key part of Improved Pharma's mission.

Key Points: 
  • WEST LAFAYETTE, Ind., Jan. 14, 2022 /PRNewswire-PRWeb/ -- Developing new tools and advancing pharmaceutical development is a key part of Improved Pharma's mission.
  • In 2021, the results from several research and development projects were published with our team of consultants and collaborators.
  • "This past year has been very exciting for the Improved Pharma team," exclaims Dr. Stephen Byrn, CSO of Improved Pharma.
  • Improved Pharma is a research, consulting, and information company dedicated to improving pharmaceutical methods, formulations, and processes.

ORIC Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update

Retrieved on: 
Monday, November 8, 2021
Securities Exchange Act of 1934, Population, Safety, GR, Biomarker, CTA, G&A, Industry, SAN, ORIC, Prostate cancer, Plasma, R, Security (finance), Part Two, PRC2, Part, CEO, Investment, D, EGFR, COVID-19, HER2, Securities Act of 1933, AR, Sale, Twitter, EED, Multiple myeloma, Patient, Neoplasm, U.S. Securities and Exchange Commission, Research, GLOBE, LinkedIn, Therapy, SEC, CD73, Pharmacokinetics, Drug Quality and Security Act, Tucatinib, ATM, Marketing, Nasdaq, Risk, IND, Lapatinib, Pharmaceutical industry, Cryptocurrency, Vaccine, Medical imaging

Strengthened board of directors with addition of Steven L. Hoerter

Key Points: 
  • Strengthened board of directors with addition of Steven L. Hoerter
    SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter ended September 30, 2021.
  • Patients are enrolled independent of GR status, with retrospective analysis of AR variants and GR expression and other potentially predictive biomarkers.
  • Enrollment continues in the Part II dose expansion cohorts at nine clinical sites across the United States.
  • ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients lives by Overcoming Resistance In Cancer.

ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC

Retrieved on: 
Thursday, October 7, 2021
Twitter, Part Two, IHC, Neoplasm, Patient, Pharmacokinetics, EGFR, ID, Risk, Ovarian cancer, Part, Lapatinib, COVID-19, Prostate cancer, AR, NSCLC, LinkedIn, Safety, Industry, Webcast, Population, SEC, Securities Exchange Act of 1934, FDA, MD, EED, U.S. Securities and Exchange Commission, CD73, Securities Act of 1933, Security (finance), ORIC, Plasma, Gene expression, Drug Quality and Security Act, Key finding attacks, Tucatinib, Therapy, PRC2, Taxane, Biomarker, GR, HER2, Medical imaging, Pharmaceutical industry, Vaccine

Patients are continuing to enroll in the expansion cohort and we look forward to reporting an update from the Phase 1b trial in 2022.

Key Points: 
  • Patients are continuing to enroll in the expansion cohort and we look forward to reporting an update from the Phase 1b trial in 2022.
  • Enrollment continues in the Part II dose expansion cohorts at nine clinical sites across the United States.
  • Based on preclinical and clinical studies, ORIC-101 is expected to have reduced drug-drug interaction liabilities than other glucocorticoid receptor antagonists.
  • ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients lives by Overcoming Resistance In Cancer.